Tu1138 Efficacy of Vedolizumab in Crohn's Disease by Prior Treatment Failure in Gemini II, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study
Stephen B. Hanauer(Northwestern University), Michael Smyth, Catherine Milch(Millennium Engineering and Integration (United States)), Jing Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Donald MacIntosh(Dalhousie University), Brian G. Feagan(Western University), Irving H. Fox(Takeda (United States))
Cited by 4
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k